Analysts Expect Kura Oncology, Inc. (KURA) to Post -$0.37 EPS
Brokerages expect Kura Oncology, Inc. (NASDAQ:KURA) to report earnings of ($0.37) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kura Oncology’s earnings, with estimates ranging from ($0.49) to ($0.29). Kura Oncology also reported earnings per share of ($0.37) during the same quarter last year. The firm is expected to issue its next earnings results after the market closes on Tuesday, November 7th.
On average, analysts expect that Kura Oncology will report full year earnings of ($1.54) per share for the current fiscal year, with EPS estimates ranging from ($1.82) to ($1.35). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.70) to ($1.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Kura Oncology.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03.
A number of analysts recently issued reports on the stock. Zacks Investment Research raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. Citigroup Inc. set a $13.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Leerink Swann reissued an “outperform” rating and set a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a research report on Thursday, August 10th. Finally, ValuEngine raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $16.00.
Large investors have recently modified their holdings of the business. State of Wisconsin Investment Board acquired a new stake in Kura Oncology in the second quarter valued at approximately $102,000. Oppenheimer & Co. Inc. grew its position in Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after acquiring an additional 1,600 shares in the last quarter. Rhumbline Advisers acquired a new stake in Kura Oncology in the second quarter valued at approximately $131,000. New York State Common Retirement Fund acquired a new stake in Kura Oncology in the second quarter valued at approximately $142,000. Finally, Nationwide Fund Advisors acquired a new stake in Kura Oncology in the first quarter valued at approximately $136,000. 40.56% of the stock is owned by institutional investors.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.